Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Shares Outstanding (2016 - 2025)

Viking Therapeutics' Shares Outstanding history spans 12 years, with the latest figure at $114.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 2.89% year-over-year to $114.8 million; the TTM value through Dec 2025 reached $114.8 million, up 2.89%, while the annual FY2025 figure was $114.8 million, 2.89% up from the prior year.
  • Shares Outstanding for Q4 2025 was $114.8 million at Viking Therapeutics, up from $112.4 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $114.8 million in Q4 2025 and bottomed at $76.7 million in Q2 2022.
  • The 5-year median for Shares Outstanding is $100.0 million (2023), against an average of $94.8 million.
  • The largest annual shift saw Shares Outstanding dropped 1.98% in 2022 before it skyrocketed 38.97% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $78.2 million in 2021, then rose by 0.01% to $78.3 million in 2022, then rose by 27.93% to $100.1 million in 2023, then increased by 11.45% to $111.6 million in 2024, then grew by 2.89% to $114.8 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Shares Outstanding are $114.8 million (Q4 2025), $112.4 million (Q3 2025), and $112.3 million (Q2 2025).